
    
      This is a prospective, randomized, double-blind, sham-controlled, multi-center post market
      study investigating the efficacy and safety of MobiusHD System, and the efficacy of the
      MobiusHD device in lowering mean systolic 24-hour ABP in subjects with resistant
      hypertension.
    
  